The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

[1]  Xiaoyun Hu,et al.  Prognostic evaluation of colorectal cancer using three new comprehensive indexes related to infection, anemia and coagulation derived from peripheral blood , 2020, Journal of Cancer.

[2]  A. Irimie,et al.  Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers , 2020, International journal of molecular sciences.

[3]  J. Hainsworth,et al.  Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. , 2019, The Lancet. Oncology.

[4]  Donna Niedzwiecki,et al.  Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Danesi,et al.  Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial , 2019, JAMA oncology.

[6]  Jeffrey S. Morris,et al.  Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. , 2019, JCO precision oncology.

[7]  J. Sicklick,et al.  Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies , 2019, JCO precision oncology.

[8]  A. Tannapfel,et al.  Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial , 2018, Front. Oncol..

[9]  A. V. van Kuilenburg,et al.  DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. , 2018, The Lancet. Oncology.

[10]  E. Van Cutsem,et al.  Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Masato Nakamura.  Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial , 2018, Annals of Oncology.

[12]  V. Heinemann,et al.  1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  E. Van Cutsem,et al.  Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  V. Adamo,et al.  Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Lenz,et al.  MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer , 2018, Clinical Cancer Research.

[16]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[17]  Joon-Oh Park,et al.  Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer , 2018, Clinical colorectal cancer.

[18]  P. Laurent-Puig,et al.  Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer , 2018, Clinical Cancer Research.

[19]  P. Gibbs,et al.  Targeted therapy for metastatic colorectal cancer , 2018, Expert review of anticancer therapy.

[20]  M. Delorenzi,et al.  Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. , 2018, European journal of cancer.

[21]  F. Nicolantonio,et al.  Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Douillard,et al.  Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study , 2018, Journal of Cancer Research and Clinical Oncology.

[23]  E. Van Cutsem,et al.  Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer , 2018, Case Medical Research.

[25]  A. Bardelli,et al.  Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. , 2018, Cancer cell.

[26]  P. Laurent-Puig,et al.  Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy , 2018, Clinical Cancer Research.

[27]  P. Gibbs,et al.  Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer , 2018, Clinical Cancer Research.

[28]  J. Tabernero,et al.  Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  G. Tonini,et al.  Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S. Kopetz,et al.  Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. , 2018 .

[31]  J. Desai,et al.  BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Drilon,et al.  RET fusions in a small subset of advanced colorectal cancers at risk of being neglected , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Ebert,et al.  Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Taieb,et al.  Colorectal Cancer: Why Does Side Matter? , 2018, Drugs.

[35]  Jeffrey W. Clark,et al.  Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis , 2018, Cancer medicine.

[36]  P. Laurent-Puig,et al.  RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  C. Nadal,et al.  Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[38]  Masato Nakamura,et al.  A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11 , 2018, Oncotarget.

[39]  C. Ishioka,et al.  Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer , 2018, Oncotarget.

[40]  A. Bardelli,et al.  Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Gary Middleton,et al.  Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. , 2018, Cancer discovery.

[42]  M. Loriot,et al.  [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. , 2018, Bulletin du cancer.

[43]  H. Grabsch,et al.  Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review , 2018, Clinical Epigenetics.

[44]  J. Roche.  Erratum: Roche, J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers, 2018, 10, 52 , 2018, Cancers.

[45]  Y. Baskın,et al.  Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature , 2018, Gastroenterology research.

[46]  Cheng Chen,et al.  New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications , 2018, Molecular Cancer.

[47]  A. Cesano,et al.  Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic , 2018, Biomedicines.

[48]  M. Gerlinger,et al.  Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. , 2018, Critical reviews in oncology/hematology.

[49]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. O’Sullivan,et al.  Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment , 2018, Oncotarget.

[51]  G. Fontanini,et al.  Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Y. Ko,et al.  ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy , 2017, Medicine.

[53]  S. Sleijfer,et al.  Molecular Tumor Boards: current practice and future needs , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  James X. Sun,et al.  ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer , 2017, Journal of the National Cancer Institute.

[55]  F. Nicolantonio,et al.  Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth , 2017, Nature.

[56]  M. Sabbatini,et al.  Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review , 2017, BioMed research international.

[57]  J. Barrett,et al.  Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer , 2017, JAMA oncology.

[58]  D. Sargent,et al.  Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials , 2017, JAMA oncology.

[59]  A. Rademaker,et al.  Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. , 2017, Journal of gastrointestinal oncology.

[60]  P. Laurent-Puig,et al.  Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial , 2017, Oncotarget.

[61]  A. Bardelli,et al.  Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  E. Van Cutsem,et al.  Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  Hidetoshi Eguchi,et al.  MicroRNAs as Biomarkers in Colorectal Cancer , 2017, Cancers.

[64]  P. Quirke,et al.  Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations , 2017, British Journal of Cancer.

[65]  Joon-Oh Park,et al.  The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer , 2017, Journal of Cancer.

[66]  P. Gibbs,et al.  Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes , 2017, European journal of cancer.

[67]  F. Ciardiello,et al.  Present and future of metastatic colorectal cancer treatment: A review of new candidate targets , 2017, World journal of gastroenterology.

[68]  A. Bardelli,et al.  Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer , 2017 .

[69]  P. Laurent-Puig,et al.  Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) , 2017, Clinical Cancer Research.

[70]  V. Heinemann,et al.  Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  Z. Aziz,et al.  Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  Elisa Ficarra,et al.  Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer , 2017, Nature Communications.

[73]  W. Scheithauer,et al.  Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. , 2017 .

[74]  P. Wirapati,et al.  VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  Jesse S. Voss,et al.  Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  U. Mansmann,et al.  Methylated free‐circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer , 2017, International journal of cancer.

[77]  T. Cenci,et al.  A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation , 2017, British Journal of Cancer.

[78]  D. Sargent,et al.  Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials , 2017, JAMA oncology.

[79]  L. Diaz,et al.  Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). , 2017 .

[80]  G. Alí,et al.  Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients , 2017, Clinical Cancer Research.

[81]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. , 2017, The Journal of molecular diagnostics : JMD.

[82]  M. Takano,et al.  UGT1A1 polymorphisms in cancer: impact on irinotecan treatment , 2017, Pharmacogenomics and personalized medicine.

[83]  M. E. Baiomy,et al.  ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy , 2017, Asian Pacific journal of cancer prevention : APJCP.

[84]  P. Laurent-Puig,et al.  Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wildtype stage III colon cancer patients , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  A. Bardelli,et al.  Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer , 2016, Nature Communications.

[86]  S. Jeffrey,et al.  Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer , 2016, Oncotarget.

[87]  M. Kloor,et al.  No association of CpG island methylator phenotype and colorectal cancer survival: population-based study , 2016, British Journal of Cancer.

[88]  Cheng Chen,et al.  MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer , 2016, Cellular Physiology and Biochemistry.

[89]  E. Frangou,et al.  Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. , 2016, The lancet. Gastroenterology & hepatology.

[90]  P. Laurent-Puig,et al.  ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8) , 2016 .

[91]  A. Bardelli,et al.  D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer , 2016 .

[92]  J. Schellens,et al.  Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  C. Jing,et al.  Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients , 2016, Oncotarget.

[95]  V. Torri,et al.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[96]  James X. Sun,et al.  Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. , 2016 .

[97]  F. Meric-Bernstam,et al.  HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. , 2016 .

[98]  R. Greil,et al.  DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. , 2016, JAMA oncology.

[99]  J. Barrett,et al.  Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. , 2016, JAMA oncology.

[100]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[101]  M. Cheang,et al.  Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC) , 2016, Oncotarget.

[102]  H. Brenner,et al.  Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review , 2016, Clinical Epigenetics.

[103]  P. Laurent-Puig,et al.  Methylator phenotype in colorectal cancer: A prognostic factor or not? , 2016, Critical reviews in oncology/hematology.

[104]  C. Schwebel,et al.  Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency , 2016, International Journal of Colorectal Disease.

[105]  M. Stauch,et al.  Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial) , 2016, International journal of cancer.

[106]  J. Kinkorová.  Biobanks in the era of personalized medicine: objectives, challenges, and innovation , 2015, EPMA Journal.

[107]  Long Bai,et al.  A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer , 2015, Scientific Reports.

[108]  J. Sanderson,et al.  Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.

[109]  R. Bosotti,et al.  Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer , 2015, Journal of the National Cancer Institute.

[110]  Gang Li,et al.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.

[111]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[112]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[114]  V. Torri,et al.  Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas , 2015, Clinical Cancer Research.

[115]  Ron Bose,et al.  HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.

[116]  Hiromu Suzuki,et al.  Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer , 2015, Annals of Surgical Oncology.

[117]  I. Nagtegaal,et al.  Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer , 2015, British Journal of Cancer.

[118]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[119]  Y. Hoshida,et al.  Cancer biomarker discovery and validation. , 2015, Translational cancer research.

[120]  Andrew M. Gross,et al.  ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer , 2015, PloS one.

[121]  M. Wiese,et al.  Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer' , 2015, British Journal of Cancer.

[122]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[123]  M. Wiese,et al.  Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer , 2015, British Journal of Cancer.

[124]  I. Nagtegaal,et al.  MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer , 2015, Oncotarget.

[125]  R. Wolff,et al.  Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. , 2015, Journal of gastrointestinal oncology.

[126]  Claudia Maggi,et al.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.

[127]  F. Molinari,et al.  eGFR signaling in colorectal cancer: a clinical perspective , 2015 .

[128]  M. Wiese,et al.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  S. Baylin,et al.  Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[130]  B. Nielsen,et al.  Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab , 2014, PloS one.

[131]  A. Bardelli,et al.  Acquired resistance to EGFR‐targeted therapies in colorectal cancer , 2014, Molecular oncology.

[132]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[133]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[134]  J. Hecht,et al.  PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  Y. Wang,et al.  Elevated HOXB9 expression promotes differentiation and predicts a favourable outcome in colon adenocarcinoma patients , 2014, British Journal of Cancer.

[136]  C. Bokemeyer,et al.  Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. , 2014 .

[137]  K. Aihara,et al.  Early Diagnosis of Complex Diseases by Molecular Biomarkers, Network Biomarkers, and Dynamical Network Biomarkers , 2014, Medicinal research reviews.

[138]  Sabine Tejpar,et al.  Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.

[139]  L. Landi,et al.  MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. , 2014, Clinical colorectal cancer.

[140]  Ming Li,et al.  UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians , 2014, Cancer Chemotherapy and Pharmacology.

[141]  E. Van Cutsem,et al.  Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). , 2014 .

[142]  T. Ciuleanu,et al.  FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC). , 2014 .

[143]  P. Gibbs,et al.  PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 , 2013, Clinical Cancer Research.

[144]  H. Samonigg,et al.  miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor , 2013, Journal of Clinical Pathology.

[145]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[146]  R. Greil,et al.  Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[147]  Susan Richman,et al.  Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial , 2013, The Lancet. Oncology.

[148]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[149]  Scott D. Patterson,et al.  Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). , 2013 .

[150]  M. Esteller,et al.  Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.

[151]  E. Van Cutsem,et al.  Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.

[152]  S. Knuutila,et al.  MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. , 2012, Cancer genetics.

[153]  P. Catalano,et al.  Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab , 2012, Clinical Cancer Research.

[154]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[155]  A. Russo,et al.  Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[156]  C. Bokemeyer,et al.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.

[157]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[158]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[159]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[160]  M. Moroni,et al.  Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study , 2011, Journal of Clinical Pathology.

[161]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[162]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[163]  Peggy H. Wong,et al.  Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. , 2011, Pharmacogenomics.

[164]  C. Punt,et al.  Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer , 2011, Clinical Cancer Research.

[165]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  G. Fontanini,et al.  Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. , 2010, The Lancet. Oncology.

[167]  J. Vandesompele,et al.  Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[169]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  M. Moroni,et al.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[173]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  B. Iacopetta,et al.  CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[175]  Jeffrey S. Morris,et al.  CpG island methylation in colorectal adenomas. , 2001, The American journal of pathology.

[176]  L. Sobin,et al.  Prognostic factors in clinical decision making , 2001, Cancer.

[177]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[178]  M. Loriot,et al.  [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. , 2018, Bulletin du cancer.

[179]  Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (combimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer , 2018 .

[180]  J. Tabernero,et al.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[181]  M. Peeters,et al.  The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. , 2018, Critical reviews in oncology/hematology.

[182]  C. Barrow,et al.  Chasing the personalized medicine dream through biomarker validation in colorectal cancer. , 2017, Drug discovery today.

[183]  A. Scarpa,et al.  Microsatellite Instability-Defective DNA Mismatch Repair: ESMO Biomarker Factsheet , 2017 .

[184]  V. Torri,et al.  Sustained Inhibition of HER 3 and EGFR Is Necessary to Induce Regression of HER 2-Ampli fi ed Gastrointestinal Carcinomas , 2015 .

[185]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. , 2014, European journal of cancer.

[186]  Jeffrey W. Clark,et al.  Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. , 2012, The oncologist.

[187]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[188]  B. Uzzan,et al.  Microsatellite instability: a predictive marker in metastatic colorectal cancer? , 2009, Targeted Oncology.